KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Non-Current Deffered Revenue: 2009-2012

Historic Non-Current Deffered Revenue for Biomarin Pharmaceutical (BMRN) over the last 2 years, with Sep 2012 value amounting to $13.1 million.

  • Biomarin Pharmaceutical's Non-Current Deffered Revenue rose 62.15% to $13.1 million in Q3 2012 from the same period last year, while for Sep 2012 it was $13.1 million, marking a year-over-year increase of 62.15%. This contributed to the annual value of $8.8 million for FY2011, which is 68.19% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Non-Current Deffered Revenue of $13.1 million as of Q3 2012, which was up 6.47% from $12.3 million recorded in Q2 2012.
  • Biomarin Pharmaceutical's Non-Current Deffered Revenue's 5-year high stood at $13.1 million during Q3 2012, with a 5-year trough of $1.7 million in Q1 2009.
  • For the 3-year period, Biomarin Pharmaceutical's Non-Current Deffered Revenue averaged around $9.1 million, with its median value being $8.8 million (2011).
  • Data for Biomarin Pharmaceutical's Non-Current Deffered Revenue shows a peak YoY soared of 68.19% (in 2011) over the last 5 years.
  • Biomarin Pharmaceutical's Non-Current Deffered Revenue (Quarterly) stood at $3.5 million in 2009, then reached $5.2 million in 2010, then soared by 68.19% to $8.8 million in 2011, then spiked by 62.15% to $13.1 million in 2012.
  • Its Non-Current Deffered Revenue stands at $13.1 million for Q3 2012, versus $12.3 million for Q2 2012 and $8.8 million for Q1 2012.